A vaccine won’t solve all our Covid problems
Today’s Oxford-AstraZeneca vaccine update has raised hopes that life in Britain could start getting back to normal by spring. But cheers in Downing Street didn’t extend to AstraZeneca’s share price, which fell by nearly three per cent in response to the news. Why the dip in the wake of such good news? AstraZeneca vaccine’s effectiveness – recorded at 70 per cent – is notably lower than its Pfizer and Moderna competitors. What’s more, the 70 per cent figure has been reached by averaging results from two groups who received the vaccine in different doses: a smaller group, who were given half a dose at first, recorded a 90 per cent efficiency rate, and